Casey O'Connell
Keck Hospital of USC · University of Southern California
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Casey O'Connell as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:00 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04873102 · Danazol for Treatment of Cytopenias in Patients With CirrhosisUniversity of Southern California · recruiting · Cirrhosis, Liver, Cytopenia · principal investigator
- N/ANCT03207854 · Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy VolunteersUniversity of Southern California · recruiting · Healthy Subject, Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid Cell Neoplasm · principal investigator
- Ph2NCT03146871 · Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating AgentUniversity of Southern California · terminated · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome · principal investigator
- Ph1/Ph2NCT02935361 · Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or RelapsedUniversity of Southern California · active not recruiting · Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Research Training and Education CoordinationP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Josh Neman-Ebrahim · fiscal years 2000 to 2026
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:00 UTC. The ranking covers the 200 most relevant of 35 PubMed records, and a shared surname and initials can bring in a namesake. All 35 on PubMed
- Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.Arch Neurol · 2004432 citationsRCR 12.6
- 235 citationsRCR 6.5
- The validity of smoking self-reports by adolescents: a reexamination of the bogus pipeline procedure.Addict Behav · 1987234 citationsRCR 14.8
- Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.Circulation · 2018185 citationsRCR 7.8
- 173 citationsRCR 7.2
- International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.J Clin Oncol · 2014169 citationsRCR 4.9
- 130 citationsRCR 11.7
- Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.Lancet Oncol · 2017125 citationsRCR 3.6
- Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.J Clin Oncol · 2022118 citationsRCR 7.5
- ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.Blood Adv · 2020117 citationsRCR 5.4